





We have read “Parkinsonism associated with gabapentinoid
drugs: a pharmacoepidemiologic study” by Pacheco-Paez and
colleagues with great interest.1 As the use of gabapentinoid
drugs increases, any information on their possible long-term
side effects is warranted. Based on the VigiBase database, the
researchers concluded that both gabapentin (GBP) and
pregabalin (PRG) have 2.16 to 2.43 times higher reporting odds
ratios (RORs) for developing parkinsonism than nonusers, indi-
cating possible adverse reactions.
However, in our opinion, the lack of numerous important
factors (e.g., age, indications, and comorbidities) prevents from
identifying any causative relationships between gabapentinoid
usage and reported parkinsonism.
While GBP has numerous on-label indications (e.g., epilepsy,
peripheral neuropathic pain caused by diabetic neuropathy, and
postherpetic neuralgia), it may be used in restless legs syndrome
(RLS), essential tremor (ET), and central- or spasticity-related
pain efficiently. Besides, PRG has an indication for generalized
anxiety and the off-label use for chronic low-back pain.
Gabapentinoid drugs are more frequently prescribed in patients
with older age, higher comorbidity index, and diabetes.2 Reim-
bursement and costs can also have an impact on the use of these
drugs. Based on the publicly available Hungarian National
Health Insurance Fund data, the vast majority of real-life
gabapentinoid usage is associated with diabetic neuropathic pain
(72.2% and 89.5% for GBP and PRG, respectively).
The interpretation of the VigiBase data without relevant
clinical data is very limited because some of the gabapentinoid
indications (e.g., type 2 diabetes mellitus [T2DM], RLS, or
ET) may be associated with higher risks for developing par-
kinsonism.3,4 For example, T2DM may increase the risk by
41%.4 Therefore, the underlying T2DM supposedly is not a
negligible factor behind the increased RORs observed with
gabapentinoid usage.
To compensate for this weakness and assess “the robust-
ness” of their findings, the researchers made some efforts.
They tried to exclude cases where other drugs capable of
inducing parkinsonism were used, but some concomitant
medications (e.g., trimetazidine5) were not taken into
consideration. The reported risks for parkinsonism con-
cerning amitriptyline and duloxetine, drugs having similar
indications with gabapentinoids, were also compared.
Although amitriptyline might have similar indications for
neuropathic pain, it has numerous contraindications,
mainly attributed to cholinergic side effects and signifi-
cantly more pharmacological interactions, limiting its use
in T2DM and the elderly. Therefore, we believe that the
comparison between gabapentinoids versus duloxetine was
more feasible. Table 2 shows that GBP and PRG usage is
associated with 0.91 (95% confidence interval [CI]:
0.86–0.96) and 1.15 (95% CI: 1.09–1.22) higher risks for
reported parkinsonism compared to duloxetine users. Con-
sidering that gabapentinoids are more frequently prescribed
in the elderly,2 where development of parkinsonism is more
probable, these differences (–9% to +15%) seem to be nei-
ther strikingly outstanding nor clinically relevant. More-
over, these data may suggest that GBP and PRG have
similar RORs for signaling parkinsonism compared to
duloxetine. This may also indicate that not the
gabapentinoid-usage alone, but other clinical factors
(e.g., T2DM and older age) might be responsible for the
increased reporting of parkinsonism. Therefore, we believe
that the methods applied by Pacheco-Paez and colleagues
are unable to answer the question of whether
gabapentinoid usage can be associated with parkinsonism.
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We read with interest the comments by Pinter and colleagues
about our article in which we suggested an association between
exposure to gabapentinoids (gabapentin, pregabalin) and the
occurrence of parkinsonism.1 The authors discussed several
points.
First, they underlined the lack of description of numerous
important factors, like age, in the description of the study popula-
tion. In fact, because of editorial recommendations (limits to the
number of tables and words), it was not possible to present all our
data in the article. In fact, we previously verified that there was no
difference between the study groups. For example, the mean age
was 63.2 10.8 years in cases and 63.6 11.1 in noncases for
gabapentin and 63.8 11.4 in cases and 64.4 11.5 in noncases for
pregabalin, whichwere not significantly different.
Second, Pinter and colleagues discussed the underlying puta-
tive role of diabetes mellitus. They mention that type 2 diabetes
mellitus increases the risk of parkinsonism by 41%. In fact, there
are many publications about diabetes mellitus and Parkinson’s
disease (PD), and there have been major conflicting results; some
studies described an association and others have been unable to
find such an association.2,3 Pinter and colleagues also pointed
out that trimetazidine, a nonantipsychotic drug known to induce
parkinsonism,4 was not in the list of excluded drugs which cause
parkinsonism in our analysis. Thus, we repeated a sensitivity
analysis that excluded trimetazidine as well as drugs used in dia-
betes (i.e., insulins and oral hypoglycemic drugs, class A10 in the
ATC [Anatomical Therapeutic Chemical] classification; these
drugs were used as a proxy for diabetes) in addition to the drugs
listed in our article. We found that ROR (reporting odds ratio)
values remained statistically significant: 2.11 (95% confidence
interval: 2.04–2.19) for gabapentin and 2.38 (2.30–2.46) for
pregabalin. The results clearly did not change with or without
inclusion of diabetes and trimetazidine.
Third, Pinter and colleagues recall that we used amitryptiline
and duloxetine as control drugs given that they have similar indi-
cations than gabapentinoids. Of course, the indications are close,
but not similar; because of their unique pharmacological profile,
it was not possible to find drugs that have similar indications to
gabapentinoids. Moreover, they claimed that amitriptyline has
cholinergic side effects. Amitriptyline, like all imipraminic antide-
pressants, possesses atropinic (i.e., anticholinergic and not cholin-
ergic) properties, which is totally different from a clinical point of
view. The results all consistently point toward an increased ROR
for pregabalin regardless of the comparator (amitriptyline,
duloxetine). We emphasized this in our last paragraph in which
we concluded that there is “an association between parkinsonism
and gabapentinoid drugs, mainly pregabalin.”
Fourth, Pinter and colleagues discussed the clinical importance
of our results, indicating that they are “neither strikingly out-
standing nor clinically relevant.” Once again, they should con-
sider that, as clearly indicated in the Methods, ROR values only
represent the risk of reporting and not the absolute risk value,
which has a clearly different clinical meaning.5-7 However, these
results should be interpreted in view of the very large and increas-
ing use of gabapentinoids, as underlined in the Introduction.
Finally, we would like to emphasize that, as we stated in the
article, the results report on a pharmacovigilance signal8,9 and
only suggest an association between exposure to gabapentinoids
and the occurrence of parkinsonism. These results warrant repli-
cation in population-based pharmacoepidemiological studies.
We thought that it was important to present this alert given
the widespread use of gabapentinoids and the putative clinical
consequences in the field of movement disorders.
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